User profiles for J Blake

Judith Blake

Professor of Mammalian Genetics
Verified email at jax.org
Cited by 80816

[PDF][PDF] CRAM

…, RK James, D Janke, P Larke, W Worley, J Blake… - SSB, 1997 - newspaper.library.tamu.edu
“Intelligence, Patriotism, Christianity, and a firm reliance on Him who has never yet forsaken
this favored land are still competent to adjust in the best way all our present difficulty.... As …

Chemoinformatics–predicting the physicochemical properties of 'drug-like'molecules

JF Blake - Current opinion in biotechnology, 2000 - Elsevier
A few major advances have occurred in the area of physicochemical modeling of organic
compounds during the past several years, spurred on by changes in the pharmaceutical …

Capitella teleta, a new species designation for the opportunistic and experimental Capitella sp. I, with a review of the literature for confirmed records

JA Blake, JP Grassle, KJ Eckelbarger - Zoosymposia, 2009 - biotaxa.org
This paper provides a morphological description of Capitella teleta sp. nov., an opportunistic
capitellid that is also commonly used as an experimental polychaete under the provisional …

The gene ontology knowledgebase in 2023

…, RC Lovering, C Logie, S Oliferenko, J Blake… - Genetics, 2023 - academic.oup.com
The Gene Ontology (GO) knowledgebase ( http://geneontology.org ) is a comprehensive
resource concerning the functions of genes and gene products (proteins and noncoding RNAs). …

Overcoming the 'value‐action gap'in environmental policy: Tensions between national policy and local experience

J Blake - Local environment, 1999 - Taylor & Francis
This paper is concerned with debates over the implementation of sustainability objectives. In
particular, it focuses on policies that address the ‘value‐action gap’ in environmental policy. …

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

X Wang, S Allen, JF Blake, V Bowcut… - Journal of medicinal …, 2021 - ACS Publications
KRAS G12D , the most common oncogenic KRAS mutation, is a promising target for the
treatment of solid tumors. However, when compared to KRAS G12C , selective inhibition of …

Consensus scoring for ligand/protein interactions

RD Clark, A Strizhev, JM Leonard, JF Blake… - Journal of Molecular …, 2002 - Elsevier
Several different functions have been put forward for evaluating the energetics of ligand
binding to proteins. Those employed in the DOCK, GOLD and FlexX docking programs have …

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

JB Fell, JP Fischer, BR Baer, JF Blake… - Journal of medicinal …, 2020 - ACS Publications
Capping off an era marred by drug development failures and punctuated by waning interest
and presumed intractability toward direct targeting of KRAS, new technologies and …

A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors

A Drilon, R Nagasubramanian, JF Blake, N Ku… - Cancer discovery, 2017 - AACR
Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic
efficacy in patients with TRK fusion–positive cancers. Although responses to TRK …

Use of highly elliptical core fibers for two-mode fiber devices

BY Kim, JN Blake, SY Huang, HJ Shaw - Optics Letters, 1987 - opg.optica.org
The four complex, almost degenerate, second-order eigenmodes of a two-mode fiber
having a circular core are reduced to two nondegenerate, linearly polarized second-order …